The HPG Axis
Hypothalamic-Pituitary-Gonadal Axis: GnRH Pulsatility, LH/FSH, and Negative Feedback
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- N/A (physiological system, not a product)
Reference only. Not medical advice.
What can go wrong
The axis itself is not a 'risk', but interventions that act on it carry the central hazard of this whole library: any exogenous androgen (testosterone, anabolic steroids, some prohormones) suppresses GnRH/LH/FSH and shuts down endogenous testosterone production AND spermatogenesis, with recovery that can take months to over a year and is occasionally incomplete. Drugs that manipulate feedback (aromatase inhibitors, SERMs, GnRH agonists/antagonists) likewise have axis-wide effects and require medical supervision. Misreading where on the axis a problem originates leads to the wrong treatment.
This is something to take to a clinician. The Atlas can tell you what is known about the hpg axis in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
The hypothalamic-pituitary-gonadal (HPG) axis is the three-tier feedback loop that governs male reproductive endocrinology. The hypothalamus releases gonadotropin-releasing hormone (GnRH) in discrete pulses; the anterior pituitary responds with luteinizing hormone (LH) and follicle-stimulating hormone (FSH); LH drives testicular Leydig-cell testosterone synthesis and FSH supports Sertoli-cell spermatogenesis. Testosterone and estradiol then feed back negatively on the hypothalamus and pituitary to restrain further GnRH/LH output. Understanding this loop is prerequisite to interpreting every lab value and every intervention in male sexual medicine: a single testosterone number is meaningless without knowing where on this circuit the signal originated.
The master control loop. Every hormone, drug, and lifestyle factor in this library acts somewhere on this circuit.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
- Primary hypogonadism
- Testicular failure: low T, HIGH LH/FSH (pituitary shouting at a deaf testis)
- Secondary hypogonadism
- Central failure: low T, LOW or inappropriately normal LH/FSH (the signal never arrives)
- Constitutional / functional suppression
- Reversible central suppression from obesity, illness, opioids, overtraining, or exogenous steroids
How it works
GnRH is secreted from hypothalamic neurons in a pulsatile rhythm; pulse FREQUENCY and AMPLITUDE encode the signal. The pituitary gonadotrophs translate these pulses into LH and FSH secretion, critically, CONTINUOUS (non-pulsatile) GnRH exposure paradoxically DESENSITIZES the pituitary and shuts the axis down, which is the basis of GnRH-agonist therapies used to chemically castrate (e.g., in prostate cancer). LH binds Leydig-cell receptors to stimulate cholesterol-to-testosterone steroidogenesis (rate-limiting step: StAR protein and the CYP11A1 side-chain cleavage enzyme). FSH acts on Sertoli cells to support spermatogenesis and induce inhibin B, which selectively suppresses FSH. Testosterone diffuses out, some is aromatized to estradiol, and BOTH steroids feed back on the hypothalamus (slowing GnRH pulses) and pituitary (blunting LH response). Estradiol is a particularly potent negative-feedback signal at the brain, which is why blocking aromatase or estrogen receptors (anastrozole, clomiphene, enclomiphene) raises LH and endogenous testosterone.
Why pulsatility is the whole game
The axis does not run on hormone CONCENTRATIONS so much as on the RHYTHM of GnRH release. Kisspeptin neurons (the KNDy network: kisspeptin/neurokinin B/dynorphin in the arcuate nucleus) are now understood to be the true pulse generator upstream of GnRH, a discovery from the 2003 GPR54/KISS1R mutation work (Seminara, de Roux). This is why metabolic and stress inputs (leptin, insulin, cortisol, inflammation) act largely THROUGH kisspeptin to modulate the axis. It also explains a clinical trap: a man with normal total testosterone can still have a deranged axis, and a man with low testosterone but HIGH LH/FSH has a fundamentally different disease than one with low testosterone and LOW LH/FSH.
What people get wrong
Often saidLow testosterone is one disease with one cause
ActuallyLow testosterone is a SYMPTOM. The axis has three tiers and the same low number can mean testicular failure, pituitary disease, hypothalamic suppression, or transient functional shutdown, each with a different workup and treatment. This is why LH and FSH must be measured, not just total T.
Often saidTaking testosterone just 'tops up' the tank
ActuallyExogenous testosterone feeds back on the hypothalamus and pituitary, suppressing LH and FSH and therefore shutting down the man's own production AND spermatogenesis. The axis cannot tell injected hormone from endogenous hormone.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
The concept of a pituitary-gonad relationship dates to the 1920s-30s isolation of gonadotropins. Roger Guillemin and Andrew Schally independently characterized hypothalamic releasing hormones, isolating and sequencing GnRH (then called LHRH) in 1971, work that earned the 1977 Nobel Prize in Physiology or Medicine. Ernst Knobil's rhesus-monkey experiments in the late 1970s established the indispensability of PULSATILE GnRH. The 2003 kisspeptin discoveries reframed the top of the axis again, and kisspeptin/neurokinin-B pharmacology is now an active drug-development frontier.
- 1971Schally and Guillemin sequence GnRH (LHRH)
- 1977Nobel Prize for hypothalamic hormone work
- 1978Knobil establishes pulsatile GnRH requirement
- 2003Kisspeptin/GPR54 identified as the upstream pulse generator
- 2010sKisspeptin and NKB analogs enter human investigation
What we do not know
- How precisely do metabolic signals (insulin, leptin) and inflammatory cytokines reset the kisspeptin pulse generator in obesity-related hypogonadism?
- Can kisspeptin/NKB-based therapies restore physiological pulsatility better than current hCG/SERM approaches?
- What share of 'idiopathic' secondary hypogonadism is actually functional and reversible?
At a glance
- GnRH pulse frequency
- ~1 pulse every 60-120 min (adult male)
- LH half-life
- ~20-30 min (pulsatile)
- FSH half-life
- ~3-4 hours (smoother profile)
- Feedback hormones
- Testosterone AND estradiol (via aromatization)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about The HPG Axis. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Knobil pulsatile GnRH (rhesus)1978
Demonstrated that pulsatile, not continuous, GnRH is required to sustain LH/FSH; continuous infusion abolished gonadotropin secretion, defining the rhythmic logic of the axis
Seminara / de Roux KISS1R2003
Loss-of-function mutations in the kisspeptin receptor cause hypogonadotropic hypogonadism, placing kisspeptin upstream as the GnRH pulse generator
Finkelstein dose-response (NEJM)2013
By clamping the axis with goserelin and adding back graded testosterone +/- anastrozole, isolated the distinct roles of testosterone and estradiol, see end-estradiol